v3.26.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2025
Mar. 27, 2026
Jun. 30, 2025
Document Document And Entity Information [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Entity File Number 001-39273    
Entity Registrant Name Lyra Therapeutics, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 84-1700838    
Entity Address, Address Line One 480 Arsenal Way    
Entity Address, City or Town Watertown    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02472    
City Area Code 617    
Local Phone Number 420-8858    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol LYRA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 11,123,580
Entity Common Stock, Shares Outstanding   1,774,882  
Documents Incorporated by Reference

None.

    
Current Fiscal Year End Date --12-31    
Amendment Flag false    
Entity Central Index Key 0001327273    
Document Fiscal Period Focus FY    
Auditor Name BDO USA, P.C.    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 243    
Auditor Opinion [Text Block]

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.